Previous 10 | Next 10 |
Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linke...
Widely Recognized Experts and AGTC Leadership Will Expand on Recent ACHM Phase 1/2 Clinical Trial Data and Discuss XLRP Milestones Webcast Scheduled from 10:00 am - 1:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technol...
Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Biosciences (RCUS) +19%...
Applied Genetic Technologies (AGTC) jumps 6.2% premarket after reporting 12-month data from its ongoing achromatopsia ((ACHM)) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.ACHM B3 12-Month Results: 12-month data, which are availab...
- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- - Dosing of pediatric patients in ACHM B3 program and ACHM A3 program is expected to be completed in August 2021 - - Conference call to review data today at 8:00am ET - ...
kamisoka/iStock via Getty Images Applied Genetic Technologies (AGTC) has added ~14.2% in the post-market after announcing that the company will present 12-month data from its Phase 1/2 Achromatopsia trials tomorrow. The results will focus on adult patients and low-dose pediatric pat...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today ...
-AGTC patient advocacy executive director will highlight the state of gene therapy trial recruitment for IRDs- GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting hu...
dinn/iStock via Getty Images BTIG analysts Yun Zhong and Xu Zou witness “an attractive opportunity in gene therapy” after seeing that many players in the field are trading closer to “52-week low than to the 52-week-high.” The gene therapy candidates will see an ...
AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of a...
News, Short Squeeze, Breakout and More Instantly...
Applied Genetic Technologies Corporation Company Name:
AGTC Stock Symbol:
NASDAQ Market:
Applied Genetic Technologies Corporation Website:
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has exte...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...